Nepafenac (AHR 9434; AL 6515) (Standard) is the analytical standard of Nepafenac ( HY-17357 ). This product is intended for research and analytical applications. Nepafenac , a nonsteroidal anti-inflammatory agent, is a topically administered COX-2 inhibitor with an IC 50 of 0.12 μM. Nepafenac exhibits only weak COX-1 inhibitory activity ( IC 50 = 64.3 μM). Nepafenac possesses unique prodrug properties, which enable it to rapidly convert into the active metabolite Amfenac ( HY-17479 ) in the ocular tissues, thereby achieving high concentrations in the retina and choroid. Nepafenac reduces inflammation and pain by inhibiting the activity of cyclooxygenase ( COX ) enzymes and thereby decreasing the production of prostaglandin PGE ₂ . Nepafenac can delay the metastasis of uveal melanoma (UM) in rabbit eyes. Nepafenac is mainly used for pain management and inflammation control after ophthalmic surgeries.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > COX | Products > Signaling Pathways > Prostaglandin Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye